Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. BSO, LLC
483
•BSO, LLC•June 27, 2025

BSO, LLC – FDA 483, Jun 27, 2025

Record Details

**FDA 483 Summary for BSO, LLC**

**Inspection Dates:** June 16-27, 2025 **Location:** Golden, CO **Company:** BSO, LLC **Type of Establishment:** Outsourcing Facility **Executive Contact:** Mr. Robert J. Kilgore, CEO

**Main Violations/Issues:**

1. **Sterilization Process Validation:** The FDA observed that BSO, LLC did not adequately validate the sterilization process for Estradiol Pellets. The firm failed to document sufficient validation for the new container-closure system and did not conduct a method suitability study or calculate a recovery factor for microbial recovery efficiency. The studies provided did not reflect the current packaging configuration, which could affect product potency and performance.

2. **Production and Process Controls:** The company lacked adequate written procedures to ensure drug products meet identity, strength, purity, and quality standards. Specifically, the visual inspection procedures did not include criteria for operator re-qualification, leading to potential oversight of defects such as "Black Speck" and "Contaminant in vial." This issue was compounded by the release of batches without resolving the root cause of these defects.

3. **Stability Program Deficiencies:** The stability program did not include specific test methods, notably lacking photostability studies for light-sensitive products.

**Regulatory Framework:** The observations are inspectional and not a final determination of compliance. BSO, LLC is expected to address these issues under the FDA"s regulatory framework to ensure product safety and efficacy.

**Required Actions:** BSO, LLC must implement corrective actions, including validating the sterilization process for current configurations, revising visual inspection procedures to include re-qualification criteria, and enhancing the stability program to include necessary test methods. The firm should also investigate and resolve the root cause of observed defects before releasing products.

Company
BSO, LLC
Inspection date
June 27, 2025
Product type
Drugs
Office
Denver District Office
Person
  • Lucila B. Nwatu (National Program Expert- Pharmacy Compounding)
View Company Profile

ID · 8bf85feb-080a-4ef2-94ea-79dfe64e5827

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BSO, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.